Home/Filings/4/0001127602-24-010605
4//SEC Filing

DeLong Mark Jeffrey 4

Accession 0001127602-24-010605

CIK 0001492422other

Filed

Mar 18, 8:00 PM ET

Accepted

Mar 19, 4:03 PM ET

Size

4.3 KB

Accession

0001127602-24-010605

Insider Transaction Report

Form 4
Period: 2024-03-18
DeLong Mark Jeffrey
Chief Business & Strat Officer
Transactions
  • Sale

    Common Stock

    2024-03-18$56.90/sh9,913$564,05054,693 total

Issuer

Apellis Pharmaceuticals, Inc.

CIK 0001492422

Entity typeother

Related Parties

1
  • filerCIK 0001856078

Filing Metadata

Form type
4
Filed
Mar 18, 8:00 PM ET
Accepted
Mar 19, 4:03 PM ET
Size
4.3 KB